Full Text Journal Articles from
Abstract 31989155

Advertisement

Find full text journal articles








COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions.

PMID: 31989155 (view PubMed database entry)
DOI: 10.1093/eurheartj/ehaa049 (read at publisher's website )
PMCID: PMC7360381 (free full text version available)

Download PDF Download PDF

Sabine Steiner, Andrej Schmidt, Thomas Zeller, Gunnar Tepe, Marcus Thieme, Lars Maiwald, Henrik Schröder, Wulf Euringer, Matthias Ulrich, Klaus Brechtel, Steffen Brucks, Erwin Blessing, Johannes Schuster, Ralf Langhoff, Sebastian Schellong, Norbert Weiss, Dierk Scheinert,

<h4>Aims</h4>Drug-coated balloons (DCBs) for femoropopliteal interventions have not been tested against each other. We aimed to directly compare efficacy and safety of a high-dose (In.Pact™) vs. low-dose (Ranger™) DCB with nominal paclitaxel densities of 3.5 vs. 2.0 μg/mm2.<h4>Methods and results</h4>Within a prospective, multicentre, non-inferiority, clinical trial 414 patients with symptomatic femoropopliteal lesions (Rutherford classification 2-4) were randomly assigned in a 1:1 ratio to endovascular treatment with either high- or low-dose DCB after stratification for lesion length. Primary efficacy and safety endpoints comprised primary patency and freedom from major adverse events (i.e. device and procedure-related deaths through 1 month, major amputations, and clinically driven target lesion revascularization through 12 months). We set a non-inferiority margin of -10% at 12 months. Total occlusions were observed frequently (>40%) and provisional stenting was performed in every fourth intervention. Non-inferiority was determined for both primary efficacy and safety endpoints at 12 months. Primary patency was 81.5% in the high-dose and 83.0% in low-dose DCB group {difference: 1.5% [lower bound of the 90% two-sided confidence interval (CI) -5.2%]; Pnon-inferiority < 0.01}. Freedom from major adverse events was determined in 92.6% in high-dose and in 91.0% in low-dose DCB group [difference -1.6% (lower bound of the 90% two-sided CI -6.5%); Pnon-inferiority < 0.01]. Overall death rate was low (2.0%) and no major amputation occurred.<h4>Conclusion</h4>Two DCBs with different coating characteristics exhibited comparable results with excellent effectiveness and safety through 12 months for femoropopliteal interventions including a wide range of lesion lengths.<h4>Clinical trial registration</h4>The trial is registered with ClinicalTrials.gov (NCT02701543).

Eur Heart J (European heart journal)
[2020, 41(27):2541-2552]

Cited: 1 time

AltMetric Statistics

Additional resources:




Advertisement


Disclaimer

0.539 s